Amantadine in Huntington's disease: open-label video-blinded study.

C Lucetti, G Gambaccini, S Bernardini, G Dell'Agnello, L Petrozzi, G Rossi, U Bonuccelli

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2003;23 Suppl 2():S83-4

PMID: 12548355

Full Text on Springer View on PubMed

Abstract

Huntington's disease (HD) is characterized by chorea, cognitive and behavioral changes. Amantadine, a non-competitive NMDA receptor antagonist, has shown an antidyskinetic effect on levodopa-induced dyskinesias, which are known to have strict pathogenetic analogies with choreic hyperkinesias. The antidyskinetic efficacy of amantadine and its effects on cognitive and behavioural symptoms were evaluated. Eight HD patients received oral amantadine (100 mg tid) unblinded for a 1-year period. A significant reduction of dyskinesias was reported ( p<0.01). No changes were observed in neuropsychologic and psychiatric assessments after 6 and 12 months of therapy. These data may have relevance to the treatment of HD with amantadine.

Address: Department of Neuroscience, University of Pisa, Pisa, Italy.

DOI: 10.1007/s100720200081

Link outs

Free resources

Medical:

https://medlineplus.gov/huntingtonsdisease.html

Subscription / membership required

Full Text Sources:

https://link.springer.com/10.1007/s100720200081

MeSH Terms: Aged, Amantadine, Dyskinesia, Drug-Induced, Excitatory Amino Acid Antagonists, Female, Humans, Huntington Disease, Hyperkinesis, Levodopa, Male, Receptors, N-Methyl-D-Aspartate, Time Factors